SEC Comment Letter for Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830) (TVRD) — Oct 5, 2017
Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830)
Date: Oct. 5, 2017 · CIK: 0001346830 · Accession: 0000000000-17-035395
AI Filing Summary & Sentiment
Reasoning
Letter
October 4, 2017 Derek Chalmers President and Chief Executive Officer Cara Therapeutics, Inc. 4 Stamford Plaza 107 Elm Street 9th Floor Stamford, Connecticut 06902 Cara Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2016 Form 10-Q for Fiscal Quarter Ended June 30, 2017 File No. 001-36279Re: Dear Dr. Chalmers: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Scott Terrillion
Show Raw Text
October 4, 2017 Derek Chalmers President and Chief Executive Officer Cara Therapeutics, Inc. 4 Stamford Plaza 107 Elm Street 9th Floor Stamford, Connecticut 06902 Cara Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2016 Form 10-Q for Fiscal Quarter Ended June 30, 2017 File No. 001-36279Re: Dear Dr. Chalmers: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Scott Terrillion